The Board of Directors of Raaj Medisafe India Limited ('the Company') at its meeting held today, i.e., 26th March, 2026, approved the allotment of 32,75,000 fully paid-up equity shares ....
FUNDRAISE
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 26 Mar 2026, 04:31 PM IST · BSE ID: 4192d949-b04f-4559-b04f-70306df7f51a
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board approved selling 32,75,000 new shares to 17 selected investors at Rs. 55 per share, raising about Rs. 18 crore in fresh capital via preferential placement.
🤖 AI Summary
- Board approved allotment of 32,75,000 fully paid equity shares at Rs. 55 per share on preferential basis
- Face value Rs. 10 per share; premium Rs. 45 per share; total raise approximately Rs. 18,01,25,000
- Seventeen investors across category; largest: Govind Maheshwari 455,900 shares (2.78%), Lifepulse Medtech 400,000 shares (2.44%)
- BSE in-principle approval received 12 March 2026; shares rank pari-passu with existing equity shares
- Listing application for allotted shares to be filed in due course; board meeting held 26 March 2026 3:45-4:15 PM
🔢 Key Numbers — exact figures from BSE filing, not rounded
Equity shares allotted
32,75,000 shares
Issue price per share
Rs. 55 (Face value Rs. 10, Premium Rs. 45)
Total capital raised
Rs. 18,01,25,000
Largest allottee shareholding post-issue
Govind Maheshwari 455,900 shares (2.78%)
Institutional investor allocation
Lifepulse Medtech Private Limited 400,000 shares (2.44%)
Combined allottee shareholding post-issue
19.94% of company equity
BSE in-principle approval date
12 March 2026
🏢 How This Affects the Company
Preferential placement brings 17 new shareholders into the company, including institutional investor Lifepulse Medtech (400,000 shares), signalling confidence in company's operations and market position.
Net cash inflow of Rs. 18,01,25,000 (32,75,000 shares × Rs. 55) credited to company capital. Share count increases from baseline to 32,75,100 outstanding shares post-allotment, diluting existing shareholder ownership.
Shareholder dilution across existing base — post-issue total shares held by named allottees represent 19.94% of company equity, introducing new stakeholders into governance structure.
👥 What This Means For Shareholders
✅
Action Required
Existing shareholders should monitor capital deployment plans; track listing approval timeline for price discovery post-allotment.
👤
Who Is Affected
All existing shareholders face ownership dilution: new allottees hold 19.94% post-issue, reducing pro-rata stake of current holders across entire shareholding base.
🔍
Management Signal
Board decision to pursue preferential placement with institutional investor (Lifepulse Medtech) and select individuals signals confidence in capital deployment strategy and organic growth roadmap.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
BSE listing approval filing for 32,75,000 allotted shares — track Reg 39 notification within 15 days of board approval
Q4 FY2026 results — verify capital deployment plan and cash utilization from Rs. 18,01,25,000 preferential placement proceeds
Share credit to demat accounts — monitor settlement and trading initiation of allotted shares post-listing approval notification
MEDIUM RISK
19.94% shareholder dilution introduces new governance stakeholders; capital deployment execution risk; listing approval pending confirmation; no clear utility disclosures for raised capital.
💡 Investor Takeaway
Board allotted 32,75,000 equity shares at Rs. 55 per share via preferential placement, raising Rs. 18,01,25,000. Institutional investor Lifepulse Medtech (400,000 shares) and 16 non-promoters participate. New shareholders collectively hold 19.94% post-allotment. Existing shareholders face 19.94% dilution. Listing application pending.
⚖️ Strengths & Concerns
✅ Positives
- Institutional investor Lifepulse Medtech participation (400,000 shares, 2.44%) signals external validation of business model and growth prospects.
- Preferential allotment secured BSE in-principle approval (12 March 2026) following documented board process, confirming regulatory compliance and transparency.
⚠️ Concerns
- Existing shareholders face dilution: 32,75,000 new shares issued; allottees collectively hold 19.94% post-issue, reducing pro-rata ownership of current holders.
- All 17 allottees are classified non-promoters (excluding one existing shareholder Kul Anand); no promoter participation in fresh capital raise evident.